PainChek (ASX:PCK) submitted a De Novo application with the US Food and Drug Administration (FDA) for the PainChek Adult app following "positive" US-based validation study results, according to a Wednesday filing with the Australian bourse.
A De Novo application is a marketing pathway for new medical devices, the filing said.
PainChek Adult is a pain assessment tool designed for aged care residents with moderate to severe dementia, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.